Twinbeech Capital LP cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 27.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,101 shares of the medical research company's stock after selling 27,962 shares during the period. Twinbeech Capital LP's holdings in IQVIA were worth $14,562,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Howard Capital Management Inc. increased its holdings in shares of IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after acquiring an additional 54 shares in the last quarter. Harbor Investment Advisory LLC grew its holdings in shares of IQVIA by 4.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock worth $253,000 after buying an additional 58 shares in the last quarter. Magnolia Capital Advisors LLC grew its holdings in shares of IQVIA by 2.9% during the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock worth $516,000 after buying an additional 74 shares in the last quarter. New York Life Investment Management LLC grew its holdings in shares of IQVIA by 0.4% during the fourth quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company's stock worth $4,537,000 after buying an additional 81 shares in the last quarter. Finally, Zions Bancorporation N.A. grew its holdings in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on IQV shares. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. UBS Group cut their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Robert W. Baird lowered their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Finally, Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $228.14.
Check Out Our Latest Research Report on IQV
IQVIA Price Performance
Shares of IQV traded down $1.08 during midday trading on Friday, hitting $136.96. The company's stock had a trading volume of 2,248,506 shares, compared to its average volume of 1,560,203. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The company's fifty day simple moving average is $155.33 and its two-hundred day simple moving average is $183.37. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $23.69 billion, a price-to-earnings ratio of 18.26, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. IQVIA's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 EPS. As a group, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
